Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C McGourty

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
British Medical Journal (Clinical Research Ed.)|December 8, 1984
Beta blockers and verapamil: a cautionary taleJ C McGourty, J H Silas
Lancet (London, England)|July 11, 1987
Beta-blockers and lipophilicityJ H Silas, J C McGourty
European Journal of Clinical Pharmacology|January 1, 1985
Comparison of once daily endralazine with placebo in the treatment of hypertension uncontrolled by a beta-blocker and diureticJ C McGourty, J H Silas, J Pidgeon
Postgraduate Medical Journal|March 1, 1985
Tolerability of combined treatment with verapamil and beta-blockers in angina resistant to monotherapyJ C McGourty, J H Silas, S A Solomon
British Journal of Clinical Pharmacology|February 1, 1988
Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosinM S Lennard, J C McGourty, J H Silas
British Journal of Clinical Pharmacology|July 1, 1985
Controlled trial of ketanserin in hypertensionJ C McGourty, J H Silas, K J Cowen
Clinical Pharmacology and Therapeutics|October 1, 1985
Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquinJ C McGourty, J H Silas, J J Fleming, et al.
British Journal of Clinical Pharmacology|December 1, 1985
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studiesJ C McGourty, J H Silas, M S Lennard, et al.
European Journal of Clinical Pharmacology|January 1, 1985
Polymorphic metabolism of metoprolol: clinical studiesJ H Silas, J C McGourty, M S Lennard, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
British Medical Journal (Clinical Research Ed.)|December 8, 1984
Beta blockers and verapamil: a cautionary taleJ C McGourty, J H Silas
Lancet (London, England)|July 11, 1987
Beta-blockers and lipophilicityJ H Silas, J C McGourty
European Journal of Clinical Pharmacology|January 1, 1985
Comparison of once daily endralazine with placebo in the treatment of hypertension uncontrolled by a beta-blocker and diureticJ C McGourty, J H Silas, J Pidgeon
Postgraduate Medical Journal|March 1, 1985
Tolerability of combined treatment with verapamil and beta-blockers in angina resistant to monotherapyJ C McGourty, J H Silas, S A Solomon
British Journal of Clinical Pharmacology|February 1, 1988
Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosinM S Lennard, J C McGourty, J H Silas
British Journal of Clinical Pharmacology|July 1, 1985
Controlled trial of ketanserin in hypertensionJ C McGourty, J H Silas, K J Cowen
Clinical Pharmacology and Therapeutics|October 1, 1985
Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquinJ C McGourty, J H Silas, J J Fleming, et al.
British Journal of Clinical Pharmacology|December 1, 1985
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studiesJ C McGourty, J H Silas, M S Lennard, et al.
European Journal of Clinical Pharmacology|January 1, 1985
Polymorphic metabolism of metoprolol: clinical studiesJ H Silas, J C McGourty, M S Lennard, et al.
Pageof 1